Search

Your search keyword '"cancer gene therapy"' showing total 193 results

Search Constraints

Start Over You searched for: Descriptor "cancer gene therapy" Remove constraint Descriptor: "cancer gene therapy" Database Academic Search Index Remove constraint Database: Academic Search Index
193 results on '"cancer gene therapy"'

Search Results

1. Utilizing adeno‐associated virus as a vector in treating genetic disorders or human cancers.

2. Gene Therapy with Chitosan Nanoparticles: Modern Formulation Strategies for Enhancing Cancer Cell Transfection.

3. Structural Evaluation of a Nitroreductase Engineered for Improved Activation of the 5-Nitroimidazole PET Probe SN33623.

4. Non‐viral Gene Therapy for Melanoma Using Lysenin from Eisenia Foetida.

5. The investigation of the death-inducing potency of a recombinant Adenovector expressing Mda-7-tlyp-1 on different cancer cell lines.

6. Application of DNA Replicons in Gene Therapy and Vaccine Development.

7. Design and Characterization of Mutated Variants of the Oncotoxic Parvoviral Protein NS1.

8. Bacteriophage-Mediated Cancer Gene Therapy.

9. Neomorphic DNA-binding enables tumor-specific therapeutic gene expression in fusion-addicted childhood sarcoma.

10. ErbB3-Targeting Oncolytic Adenovirus Causes Potent Tumor Suppression by Induction of Apoptosis in Cancer Cells.

11. Deficiency of the splicing factor RBM10 limits EGFR inhibitor response in EGFR-mutant lung cancer.

12. HydrAd: A Helper-Dependent Adenovirus Targeting Multiple Immune Pathways for Cancer Immunotherapy.

13. A pH- and Bioreducible Cationic Copolymer with Amino Acids and Piperazines for Adenovirus Delivery.

14. BET bromodomain protein inhibition reverses chimeric antigen receptor extinction and reinvigorates exhausted T cells in chronic lymphocytic leukemia.

15. Immunostimulatory bacterial antigen-armed oncolytic measles virotherapy significantly increases the potency of anti-PD1 checkpoint therapy.

16. Combination of ARE and HRE cis-Regulatory Elements Elevates the Activity of Tumor-Specific hTERT Promoter.

17. Delivery of CRISPR/Cas systems for cancer gene therapy and immunotherapy.

18. Acylation of the antimicrobial peptide CAMEL for cancer gene therapy.

19. Sleeping Beauty-engineered CAR T cells achieve antileukemic activity without severe toxicities.

20. Construction of replication-competent oncolytic retroviral vectors expressing R peptide-truncated 10A1 envelope glycoprotein.

21. Anisamide-targeted PEGylated gold nanoparticles designed to target prostate cancer mediate: Enhanced systemic exposure of siRNA, tumour growth suppression and a synergistic therapeutic response in combination with paclitaxel in mice.

22. T cells genetically engineered to overcome death signaling enhance adoptive cancer immunotherapy.

23. Evaluating the abilities of diverse nitroaromatic prodrug metabolites to exit a model Gram negative vector for bacterial-directed enzyme-prodrug therapy.

24. Biological and therapeutic viewpoints towards role of miR-218 in human cancers: Revisiting molecular interactions and future clinical translations.

25. Cell cycle checkpoint control: The cyclin G1/Mdm2/p53 axis emerges as a strategic target for broad-spectrum cancer gene therapy - A review of molecular mechanisms for oncologists.

26. Mesenchymal stem cells expressing interleukin-18 inhibit breast cancer in a mouse model.

27. Efficient Therapeutic Protein Expression Using Retroviral Replicating Vector with 2A Peptide in Cancer Models.

28. The First Approved Gene Therapy Product for Cancer Ad- p53 (Gendicine): 12 Years in the Clinic.

29. Mutagenic Analysis of an Adeno-Associated Virus Variant Capable of Simultaneously Promoting Immune Resistance and Robust Gene Delivery.

30. A hydrogel matrix prolongs persistence and promotes specific localization of an oncolytic adenovirus in a tumor by restricting nonspecific shedding and an antiviral immune response.

32. Magnetic nanoparticles for efficient cell transduction with Semliki Forest virus.

33. Nonviral cancer gene therapy: Delivery cascade and vector nanoproperty integration.

34. Nanoparticles for cancer gene therapy: Recent advances, challenges, and strategies.

35. Metastatic Ovarian Cancer Can Be Efficiently Treated by Genetically Modified Mesenchymal Stromal Cells.

36. Interferon-Inducible Mx Promoter-Driven, Long-Term Transgene Expression System of Interferon-β for Cancer Gene Therapy.

37. RNAi Screening of the Glucose-Regulated Chaperones in Cancer with Self-Assembled siRNA Nanostructures.

38. Role of nanotechnology and gene delivery systems in TRAIL-based therapies.

39. The Evaluation and Comparison of Transcriptionally Targeted Noxa and Puma Killer Genes to Initiate Apoptosis Under Cancer-Specific Promoter CXCR1 in Hepatocarcinoma Gene Therapy.

40. hTERT and BIRC5 gene promoters for cancer gene therapy: A comparative study.

41. Cellular heterogeneity mediates inherent sensitivity- specificity tradeoff in cancer targeting by synthetic circuits.

42. Alphavirus vectors as tools in neuroscience and gene therapy.

43. 6-Methylpurine derived sugar modified nucleosides: Synthesis and evaluation of their substrate activity with purine nucleoside phosphorylases.

44. Progress and problems with the use of suicide genes for targeted cancer therapy.

45. Selection of microRNA for providing tumor specificity of transgene expression in cancer gene therapy.

46. 6-Methylpurine derived sugar modified nucleosides: Synthesis and in vivo antitumor activity in D54 tumor expressing M64V-Escherichia coli purine nucleoside phosphorylase.

47. Long-term gene therapy with Del1 fragment using nonviral vectors in mice with explanted tumors.

48. Hepatoma targeting peptide conjugated bio-reducible polymer complexed with oncolytic adenovirus for cancer gene therapy.

49. Polymeric oncolytic adenovirus for cancer gene therapy.

50. A phase III study of belagenpumatucel-L, an allogeneic tumour cell vaccine, as maintenance therapy for non-small cell lung cancer.

Catalog

Books, media, physical & digital resources